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The Editorial on the Research Topic
Organ Fibrosis: Triggers, Pathways, and Cellular Plasticity
Pathological scar formation, i.e., fibrosis, is an integral part of the pathophysiological mechanism 
underlying organ failure and disease progression in a multitude of pathologies including Crohn’s 
disease, non-alcoholic steatohepatitis, and chronic kidney disease (CKD). As a consequence, fibrotic 
diseases account for up to 45% of deaths in the developed world (1). The fibrotic process is char-
acterized by the excessive production and deposition of extracellular matrix (ECM) proteins, such 
as collagens, mainly by activated profibrotic fibroblasts. The disturbed equilibrium between ECM 
formation and degradation is the end result of a complex cascade of cellular and molecular responses 
initiated by organ damage, and even though there is a range of organ-specific triggers, the fibrotic 
process and associated signaling pathways are highly conserved between different organs. Although 
the cellular and molecular mechanisms driving fibrogenesis have been meticulously dissected in 
the last decades, novel insights into this complex pathological process keep arising. In this Research 
Topic, experts from all over the world delineate the latest findings pertaining to the diverse triggers, 
signaling pathways, and cell types associated with the induction and perpetuation of fibrogenic 
events.
As stated before, fibrosis can be induced by a variety of stimuli, some of which are non-specific 
and can affect all organs, e.g., inflammation, while other triggers are clearly associated with a specific 
pathology and organ, e.g., glomerular IgA deposition (2). The article by Simon and Hertig details 
how changes in fatty acid oxidation by transient acute kidney injury (AKI) can lastingly alter the 
epithelial features of renal proximal tubular cells. This change in phenotype promotes fibrogenesis, 
illustrating that AKI can be a cause of CKD and fibrosis (Simon and Hertig). In the review by Mutsaers 
et al., it is detailed how uremic retention solutes stimulate glomerular sclerosis as well as interstitial 
fibrosis. Furthermore, they describe that on a cellular level, uremic solutes induce fibrogenic events 
by promoting, among others, epithelial-to-mesenchymal transition and senescence (Mutsaers et al.). 
Regarding scar formation in the skin, Cremers et al. show that mechanical stress mitigated wound 
healing, which was associated with an enhanced inflammatory response and prolonged survival of 
fibroblast resulting in a profibrotic environment. Furthermore, they postulate that the cytoprotective 
enzyme heme oxygenase-1 is an interesting target for the treatment of fibrosis (Cremers et al.). These 
articles nicely reiterate the diversity of profibrotic triggers, ranging from the biochemical to the 
physical, indicating that there is still a plethora of potential therapeutic targets to be investigated in 
the coming years.
Historically, transforming growth factor (TGF)-β has been regarded as one of the key factors 
driving the fibrotic response in most organs. Binding of TGF-β to its receptor initiates a multifaceted 
response orchestrated by several SMAD proteins and signaling cofactors that dictate the final tran-
scriptional response in a cell (3). However, as extensively described in the article by Piersma et al., the 
TGF-β pathway does not operate as a single entity but rather as part of an intricate signaling network 
composed of multiple signaling pathways including Wingless/Int (WNT) and yes-associated protein 
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1 (YAP)/transcriptional coactivator with PDZ-binding motif 
(TAZ) signaling, illustrating the complexity of fibrotic diseases.
Next to the diverse signaling pathways, a variety of (organ-
specific) cells are involved in the fibrotic process including 
hepatic stellate cells (HSCs), renal pericytes, and circulating 
bone marrow-derived cells (4, 5). Interestingly, it appears that 
the latter cell type can acquire both a profibrotic as well as an 
antifibrotic phenotype as delineated in the article by Adhyatmika 
et al. Antifibrotic macrophages are tasked with the removal of 
fibrotic ECM and can be identified by the expression of, among 
others, matrix-degrading enzymes and collagen-uptake recep-
tors. The concept of cell therapy for fibrosis with the notion 
that it is possible to identify and potentially recruit antifibrotic 
macrophages to fibrotic lesions foreshadows some exciting times 
to come.
Another interesting treatment modality revolves around the 
cytokine interferon gamma (IFNγ). The potent antifibrotic effects 
of IFNγ have been recognized for decades, yet this knowledge has 
never been successfully translated into a therapeutic application. 
The article by van Dijk et al. details the development of a construct 
that allows for HSC-specific delivery of IFNγ, thereby greatly 
improving the antifibrotic efficacy of this cytokine and reducing 
systemic side effects. This comprehensive review illustrates the 
feasibility of a targeted treatment for fibrosis, and we are curious 
to see how this research field will move forward.
All authors contributing to this Research Topic have made 
a tremendous effort to provide a scholarly overview of novel 
knowledge in the field of fibrosis research. It was a pleasure to 
work on this Topic, and we hope that the articles will provide 
the readers with a deeper understanding of fibrogenesis, thereby 
providing new vigor to the field and stimulating new avenues of 
research.
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